Quantum Genesis AI Corp. (OTC: QGAI) issued a press release on May 19, 2026, to clarify the relationship between its research activities and those of Quantumzyme LLP, a separate entity based in Bengaluru, India. The Company emphasized that Quantumzyme LLP is not a subsidiary or affiliate, but certain prior press releases referenced scientific publications that listed Quantumzyme affiliations due to the researchers' affiliations at the time of submission.
The clarification comes after press releases on November 5, 2025 and February 12, 2026 referenced research in the enzyme engineering and biocatalysis field. The Company now distinguishes Quantumzyme LLP from itself and provides context regarding intellectual property (IP) rights transferred under the Asset Purchase Agreement dated February 21, 2023, and a subsequent confirmatory assignment filed on April 29, 2026.
According to the Company, CEO Naveen Kulkarni transferred certain IP, know-how, methodologies, and research materials to Quantum Genesis AI as part of the 2023 agreement. The Company believes that research conducted by Mr. Kulkarni, whether directly or through Quantumzyme LLP, related to the core enzyme engineering and biocatalysis platform falls within the scope of the transferred rights. This includes technology, computational approaches, and related IP derived from the transferred platform.
The Company’s prior disclosures regarding scientific publications were based on its ownership of the relevant IP and technology. This clarification aims to provide additional context and transparency for investors and stakeholders, ensuring a clear understanding of the Company’s asset base and research boundaries.
Quantum Genesis AI Corp. is focused on advancing technologies at the intersection of AI, computational modeling, and scientific innovation, using data-driven tools to support research and development across emerging sectors. The Company maintains a commitment to transparency and responsible corporate governance.
For more information, visit the Company’s website at qgaicorp.com and its profile on OTC Markets at otcmarkets.com/stock/QGAI.
